Search
Sunday 9 August 2015
  • :
  • :
Latest Update

Pre- Market News Review: NovaGold Resources (NYSEMKT:NG), New York REIT (NYSE:NYRT), Ironwood Pharmaceuticals, (NASDAQ:IRWD), VASCO Data Security International, (NASDAQ:VDSI)

On Friday, NovaGold Resources Inc. (USA) (NYSEMKT:NG)’s shares inclined 2.24% to $3.20.

NOVAGOLD RESOURCES INC. (NG) released its second quarter financial results and updates for its flagship 50%-owned Donlin Gold project (the “Project”) in Alaska and its 50%-owned Galore Creek copper-gold-silver project in British Columbia.

NovaGold Resources Inc. explores and develops mineral properties in Canada and the United States. The company primarily explores for gold, silver, and copper deposits. Its flagship project is the 50%-owned Donlin Gold project covering an area of 81,361 acres located in the Kuskokwim region of southwestern Alaska. The company was formerly known as NovaCan Mining Resources (1985) Limited and changed its name to NovaGold Resources Inc. in March 1987. NovaGold Resources Inc. was founded in 1984 and is based in Vancouver, Canada.

New York REIT Inc (NYSE:NYRT)’s shares gained 1.39% to $10.19.

New York REIT Inc (NYRT) declared that Randolph C. Read has been designated Non-Executive Chairman of the Company’s Board of Directors (the “Board”), and the Board has been overwhelmingly re-elected at recently’s shareholders meeting. Mr. Read, who has served as a director on the Board since December 2014, will succeed William M. Kahane, who will continue to serve as a director.

Co presently, in line with its commitment to maximize long-term stockholder value, NYRT declared that the Board has authorized the Company to repurchase up to $150 million of the Company’s common stock. Additionally, the Board has authorized the engagement of Cushman & Wakefield and Holiday Fenoglio Fowler to sell certain of the Company’s non-core assets as part of the Company’s efforts to focus on high quality New York City real estate generating comprising, stable returns and providing noteworthy long-term capital appreciation opportunities.

New York REIT, Inc. focuses on acquiring commercial real estate, in addition to acquiring properties or making other real estate investments that relate to office, retail, multi-family residential, industrial, and hotel property types located primarily in New York City. It intends to qualify as a real estate investment trust for the U.S. federal income tax purposes. The company was formerly known as American Realty Capital New York Recovery REIT, Inc. New York REIT, Inc. was founded in October 2009 and is based in New York, New York.

At the end of Friday’s trade, Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)‘s shares dipped -0.52% to $11.44.

AstraZeneca Pharmaceuticals Co., Ltd. and Ironwood Pharmaceuticals, Inc. (IRWD) declared recently that top-line data demonstrate linaclotide met all primary and secondary endpoints, covering multiple abdominal and constipation symptoms, in a Phase III clinical trial of adults with irritable bowel syndrome with constipation (IBS-C). The trial was conducted primarily in China and the companies intend to file in early 2016 for China Food and Drug Administration (CFDA) approval to market linaclotide. Linaclotide is presently approved in the United States for the treatment of adults with IBS-C or chronic idiopathic constipation (CIC) and in a number of other countries for adults with IBS-C.

Ironwood Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Constella name in the European Union. It has partnershipagreements with Actavis plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, in addition to in China, Hong Kong, and Macau.

VASCO Data Security International, Inc. (NASDAQ:VDSI), ended its Friday’s trading session with -0.18% loss, and closed at $27.42.

VASCO Data Security International, Inc. (VDSI) a global leader in authentication, electronic signatures, and identity administration, declared recently that it will release its second quarter 2015 financial results after market close Tuesday, July 28, 2015.

VASCO Data Security International, Inc., together with its auxiliaries, designs, develops, markets, and supports hardware and software security systems that manage and secure access to information assets worldwide. The company offers VACMAN Controller, a host system software authentication platform that combines technologies in one platform; IDENTIKEY Authentication Server that adds server functionality to the VACMAN core authentication platform; DIGIPASS as a Service, a cloud-based authentication service primarily for enterprise customers; and MYDIGIPASS solutions for end user authentication in the cloud.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.

 




Leave a Reply

Your email address will not be published. Required fields are marked *